Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
about
Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer AscitesA randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.Tumor angiogenesis revisited: Regulators and clinical implications.NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy.The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate.Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.Clinical trials in gynecologic oncology: Past, present, and future.The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.The role of tumor microenvironment in resistance to anti-angiogenic therapy.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.
P2860
Q33904378-F711DF67-9C29-4B27-AAFF-9E7691EAF27EQ37474683-F6844B27-D7D4-426D-A549-932BCA55E25AQ37620476-20B08F41-0EDD-4101-BBE6-7AAF18B9430CQ38822258-41E4B649-FFE3-414C-AA98-F5A1EE0075B4Q39393740-D09EC0F2-7D66-4CF1-8BDD-9236E8F6FBC4Q41911962-94FB436D-3431-47E3-A262-66C72891296DQ46807630-1C7592EE-5DA7-49AE-A164-5A4907A8AF16Q47096976-046FEFDA-C64B-4144-9134-775B0987C8EEQ47566245-092A44B5-98A6-411A-B403-FE9D80604691Q47796770-3288589C-3F6E-4831-B899-7A0BD5E6E94AQ49302678-47670204-63E5-4856-AB1C-1F199515A64AQ51795514-9322978A-49F1-43F2-99A2-28EC22A0F2FDQ52645823-D7145286-89F6-4CC4-85A7-C9F8A6D1E083Q55365628-FDB20289-260A-47B3-9B51-96D297C53E31
P2860
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Randomized Phase II Evaluation ...... ecologic Oncology Group Study.
@en
Randomized Phase II Evaluation ...... ecologic Oncology Group Study.
@nl
type
label
Randomized Phase II Evaluation ...... ecologic Oncology Group Study.
@en
Randomized Phase II Evaluation ...... ecologic Oncology Group Study.
@nl
prefLabel
Randomized Phase II Evaluation ...... ecologic Oncology Group Study.
@en
Randomized Phase II Evaluation ...... ecologic Oncology Group Study.
@nl
P2093
P2860
P356
P1476
Randomized Phase II Evaluation ...... ecologic Oncology Group Study.
@en
P2093
Bradley J Monk
Carol Aghajanian
Christopher J Darus
Gregory Sutton
Jai Balkissoon
Jeanne M Schilder
Joan L Walker
Krishnansu S Tewari
Lainie P Martin
Michael W Sill
P2860
P304
P356
10.1200/JCO.2015.65.8153
P407
P577
2016-05-23T00:00:00Z